The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
暂无分享，去创建一个
Laura D. Healy | O. McCarty | B. Druker | A. Gruber | J. Aslan | R. Rigg | C. P. Loren | M. S. Nowak | Rachel A. Rigg | Cassandra P. Loren | Marie S. Nowak